You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

naxitamab

Showing 1 - 12 of 12
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroblastoma Trial in Guangzhou (Naxitamab monotherapy, GM-CSF, Irinotecan)

Recruiting
  • Neuroblastoma
  • Naxitamab monotherapy
  • +6 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 31, 2023

Neuroblastoma Trial (Naxitamab)

Not yet recruiting
  • Neuroblastoma
  • Naxitamab
  • (no location specified)
Sep 18, 2023

Ewing Sarcoma Trial in Warsaw (Naxitamab)

Not yet recruiting
  • Ewing Sarcoma
  • Naxitamab
  • Warsaw, Mazowian, Poland
    Mother and Child Institute
Jul 28, 2023

High-risk Neuroblastoma Trial in Charlotte (Naxitamab, Ceritinib)

Not yet recruiting
  • High-risk Neuroblastoma
  • Charlotte, North Carolina
    Levine Children's Hospital
Aug 4, 2022

Neuroblastoma Recurrent Trial in Worldwide (Naxitamab and GM-CSF in combination with irinotecan and temozolomide)

Terminated
  • Neuroblastoma Recurrent
  • Naxitamab and GM-CSF in combination with irinotecan and temozolomide
  • Hong Kong, Hong Kong
  • +2 more
Nov 8, 2022

Anatomic Stage IV Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma Trial in Columbus (procedure, drug, biological)

Not yet recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • HER2-Negative Breast Carcinoma
  • Biospecimen Collection
  • +5 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Aug 30, 2023

Neuroblastoma Trial in Worldwide (GM-CSF + Naxitamab)

Recruiting
  • Neuroblastoma
  • GM-CSF + Naxitamab
  • Gainesville, Florida
  • +22 more
Aug 29, 2022

Neuroblastoma Trial in Worldwide (Naxitamab, GM-CSF, Isotretinoin)

Recruiting
  • Neuroblastoma
  • Naxitamab
  • +2 more
  • Kowloon, Hong Kong
  • +8 more
Jan 31, 2022

High-Risk Neuroblastoma Trial in New York (Naxitamab/GM-CSF)

Approved for marketing
  • High-Risk Neuroblastoma
  • Naxitamab/GM-CSF
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Apr 13, 2021

Recurrent Osteosarcoma Trial in Los Angeles, New York, Houston (humanized anti-GD2 antibody, GM-CSF)

Recruiting
  • Recurrent Osteosarcoma
  • humanized anti-GD2 antibody
  • GM-CSF
  • Los Angeles, California
  • +2 more
Dec 22, 2022

Neuroblastoma Trial in Los Angeles (Dinutuximab with Chemotherapy)

Not yet recruiting
  • Neuroblastoma
  • Dinutuximab with Chemotherapy
  • Los Angeles, California
    Childrens Hospital Los Angeles
Jun 13, 2022

Osteosarcoma in Children Trial (Dinutuximab beta)

Not yet recruiting
  • Osteosarcoma in Children
  • Dinutuximab beta
  • (no location specified)
Sep 23, 2022